Single nucleotide change in the cannabinoid receptor-1 (CNR1) gene in colorectal cancer outcome

Oncology

Volumn 76, Issue 6, 2009, Pages 435-441

  Bedoya, Fernando ^a   Rubio, Juan C ^a   Morales Gutierrez, Carlos ^b   Abad Barahona, Alfredo ^b   Lora Pablos, David ^c   Meneu, Juan C ^b   Moreno Gonzalez, Enrique ^b   Enriquez De Salamanca, Rafael ^a   Vegh, Irene ^a,c  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b Department of Surgery ^*  (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Cannabinoid receptor 1; Clinical outcome; Colorectal cancer; Prognostic factors; Single nucleotide change

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; LIGAND;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GROWTH; CNR1 GENE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; CARCINOMA; COLORECTAL TUMOR; DNA SEQUENCE; GENETICS; HETEROZYGOTE; HOMOZYGOTE; MIDDLE AGED; MORTALITY; POINT MUTATION; RISK; TREATMENT OUTCOME;

AGED; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LIGANDS; MALE; MIDDLE AGED; POINT MUTATION; RECEPTOR, CANNABINOID, CB1; RISK; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME;

EID: 65449125869     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000217263     Document Type: Article

References (27)

1. Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, Uhl GR: Endocan-nabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002;66:307-344.
2. Massa F, Storr M, Lutz B: The endocannabinoid system in the physiology and pathophysiology of the intestinal tract. J Mol Med 2005;83:944-954.
3. 1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001;24:189-203.
4. Di Marzo V, Izzo AA: Endocannabinoid overactivity and intestinal inflammation. Gut 2007;55:1373-1376.
5. Ligresti A, Bisogno T, Matias I, De-Petrocellis L, Cascio MG, Cosenza V, DArgenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V: Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677-687.
6. 6-Izzo AA, Aviello G, Petrosino S, Orlando P, Marsicano G, Lutz B, Borrelli F, Capasso R, Nigam S, Capasso F, Di Marzo V: Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 2008;86:89-98.
7. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA: Antineoplasic activity of cannabinoids. J Natl Cancer Inst 1975;55:597-602.
8. Bifulco M, Di Marzo V: Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002;8:547-550.
9. Spindler KLG, Nielsen JN, Ornskov D, Brandslund I, Jakobsen A: Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. Acta Oncol 2007;17:1-5.
10. Cheirsilpa A, Ruangvejvorachai P, Karalak A, Sangprakarn S, Pummai S, Sangrajrang S: Determination of epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Cancer Ther 2007;5:137-142.
11. Gonzalez JF, Vicioso L, Alvarez M, Sevilla I, Marques E, Gallego E, Alonso L, Matilla A, Alba E: Association between VEGF expression in tumor-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. Cancer Biomark-ers 2007;3:325-333.
12. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH: Vascular endothelial growth factor gene polymorphism associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008;14:62-66.
13. Morales-Gutierrez C, Vegh I, Colina F, Go-mez-Cámara A, Garcia CA, Landa JI, Ballesteros D, Carreira PE, Enriquez-de-Salamanca R: Survival of patients with colorectal carcinoma. Cancer 1999;86:1675-1681.
14. Halling KC, French AJ, McDonnell SK, Burgart LJ, Schaid DJ, Peterson BJ, Moon-Tasson L, Mahoney MR, Sargent DJ, O'Connell MJ, Witzing TE, Farr GH Jr, Goldberg RM, Tribodeau SN: Microsatellite instability and 8p allelic imbalance in stage B2and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-1303.
15. Vegh I, De-la-Cruz J, Navarro S, Morales C, Colina F, Abad A, De-la-Calle A, Enriquez-de-Salamanca R, Moreno-Gonzalez E: Colorectal cancer relapse allelic alterations associated with tumour marker overexpression. Oncology 2003;65:146-151.
16. Diep CB, Thorstensen L, Meling GI, Skovlund E, Rognum TO, Lothe RA: Genetic tumor markers with prognostic impact in Dukes' stage B and C colorectal cancer. J Clin Oncol 2003;21:820-829.
17. Han HS, Park Y-M, Hwang TS: Differential expression of Bcl-2, Bcl-Xl and p53in colorectal cancer. J Gastroenterol Hepathol 2006;21:1108-1114.
18. Jass JR, Sobin LH: Histological Typing of Intestinal Tumours, ed 2. Berlin, Springer-Verlag, 1989.
19. Sobin LH, Wittekind CH, Akerley W: TNM Classification of Malignant Tumours, ed 6. New York, Wiley-Liss, 2002.
20. Gadzicki D, Müller-Vahl K, Stuhrmann M: A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999;13:321-323.
21. Fogli S, Breschi MC: The molecular bases of cannabinoid action in cancer.. Cancer Ther 2008;6:103-145.
22. Joseph J, Niggermann B, Zaenker KS, Entschladen F: Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 2004;53:723-728.
23. Scorticati C, Mohn C, De Laurentis A, Vissio P, Fernandez Solari J, Seilicovich A, McCann SM, Rettori V: The effect of anandamide on prolactin secretion is modulated by estrogen. Proc Natl Acad Sci USA 2003;100:2134-2139.
24. Scorticati C, Fernández-Solari J, De Lauren-tis A, Mohn C, Prestifilippo JP, Lasaga M, Seilicovich A, Billi S, Franchi A, McCann SM, Rettori V: The inhibitory effect of anan-daminde on luteinizing-hormone- realizing hormone secretion is reversed by estrogen. Proc Natl Acad Sci USA 2004;101:11891-11896.
25. Wenger T, Tóth BE, Martin BR: Effect of anandamide (endogen cannabinoid) on anterior pituitary hormone secretion in adult ovariectomized rats. Life Sci 1995;56:2057-2063.
26. Weindenfeld J, Feldman S, Mechoulam R: Effect of brain constituent, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis. Neuroendocrinology 1994;59:110-112.
27. Xu X, Liu Y, Huang S, Liu G, Xie C, Zhou J, Fan W, Li Q, Wang Q, Zhong D, Miao X: Overexpression of cannabinoid receptors CB1and CB2correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006;171:31-38.